Maze Therapeutics (MAZE) Retained Earnings (2024 - 2026)

Maze Therapeutics has disclosed Retained Earnings across 3 years of filings, most recently posting -$513.8 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$513.8 million, down 31.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$513.8 million (down 31.34% YoY), and the FY2025 annual result was -$489.5 million, down 36.58% from the prior year.
• Retained Earnings came in at -$513.8 million for Q1 2026 at Maze Therapeutics, down from -$489.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$358.4 million in Q4 2024 to a low of -$513.8 million in Q1 2026.
• The 3-year median for Retained Earnings is -$439.9 million (2025), against an average of -$438.8 million.
• Across the five-year window, Retained Earnings plunged 36.58% in 2025 and slumped 31.34% in 2026, its largest moves.
• Maze Therapeutics' Retained Earnings stood at -$358.4 million in 2024, then sank by 36.58% to -$489.5 million in 2025, then decreased by 4.95% to -$513.8 million in 2026.
• The last three Retained Earnings figures came in at -$513.8 million (Q1 2026), -$489.5 million (Q4 2025), and -$455.0 million (Q3 2025), per Business Quant data.